Author response for 'Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrazole) combined with <scp>mTOR</scp> inhibitor (Vistusertib) in endometrial cancer: translational study from the <scp>VICTORIA</scp> trial in collaboration with the <scp>GINECO</scp> group'